scholarly journals Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report

2021 ◽  
Vol 28 (6) ◽  
pp. 5401-5407
Author(s):  
Cristina Luongo ◽  
Tommaso Porcelli ◽  
Francesca Sessa ◽  
Maria Angela De Stefano ◽  
Francesco Scavuzzo ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Thyroid Cancer ◽  
Unusual Case ◽  
Tumor Response ◽  
Clinical Course ◽  
Anaplastic Thyroid Cancer ◽  
Cytotoxic Chemotherapy ◽  
Salvage Treatment ◽  
Long Period ◽  
Personalized Approach

Anaplastic thyroid cancer (ATC) is a rare but aggressive thyroid cancer, responsible for about 50% of all thyroid cancer-related deaths. During the last two decades, the development of a multimodal personalized approach resulted in an increased survival. Here, we present an unusual case of a 54-year old woman with a paucicellular metastatic ATC, a rare variant of ATC, who was treated with a combination of surgery, radiation therapy and cytotoxic chemotherapy. More than two years later, when the disease was rapidly growing, a combination of lenvatinib and pembrolizumab induced a partial tumor response of lung metastasis that persisted over 18 months. Paucicellular ATC may initially show a less aggressive behavior compared to other histological ATC variants. However, over the time, its clinical course can rapidly progress like common ATC. The combination of lenvatinib and pembrolizumab was effective as a salvage therapy for a long period of time.

Synergistic anticancer activity of sorafenib, paclitaxel, and radiation therapy on anaplastic thyroid cancer in vitro and in vivo

Head & Neck ◽  
2020 ◽  
Vol 42 (12) ◽  
pp. 3678-3684
Author(s):  
Soo Young Kim ◽  
Seok‐Mo Kim ◽  
Hojin Chang ◽  
Hang‐Seok Chang ◽  
Cheong Soo Park ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Thyroid Cancer ◽  
Anticancer Activity ◽  
Anaplastic Thyroid Cancer

scholarly journals Outcomes Following Radiation Therapy for Anaplastic Thyroid Cancer

2018 ◽  
Vol 100 (5) ◽  
pp. 1380
Author(s):  
A. Bell ◽  
J. Ma ◽  
B. Lok ◽  
J.E. Leeman ◽  
C.J. Tsai ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Thyroid Cancer ◽  
Anaplastic Thyroid Cancer

scholarly journals Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models

2021 ◽  
Vol 22 (2) ◽  
pp. 536
Author(s):  
Hyeok Jun Yun ◽  
Hee Jun Kim ◽  
Jungmin Kim ◽  
Sang Yong Kim ◽  
Hang-Seok Chang ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Radiation Therapy ◽  
Thyroid Cancer ◽  
Combination Therapy ◽  
Intracellular Signaling ◽  
Xenograft Model ◽  
Anaplastic Thyroid Cancer ◽  
Anticancer Effect ◽  
Mouse Xenograft Model

Anaplastic thyroid cancer (ATC) is an undifferentiated and advanced form of thyroid cancer, accompanied with a high ratio of epigenetic adjustment, which occurs more than genetic mutations. In this study, we aimed to evaluate the synergistic anticancer effect (in vitro and in vivo) of the new combination of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) and sorafenib with radiation therapy in pre-clinical models of ATC. The ATC cell lines, YUMC-A1 and YUMC-A2, were isolated from the current patients who were treated with HNHA and sorafenib, either as monotherapy or combination therapy. Synergistic anticancer effect of the combination therapy on the intracellular signaling pathways and cell cycle was assessed via flow cytometry and immunoblot analysis. To examine tumor shrinkage activity in vivo, an ATC cell line-derived mouse xenograft model was used. Results showed that the combination therapy of HNHA and sorafenib with radiation promoted tumor suppression via caspase cleavage and cell cycle arrest in patient-derived ATC. In addition, the combination therapy of HNHA and sorafenib with radiation was more effective against ATC than therapy with HNHA or sorafenib with radiation. Thus, the combination of HNHA and sorafenib with radiation may be used as a novel curative approach for the treatment of ATC.

scholarly journals Anaplastic thyroid cancer. Is there a light at the end of the tunnel?

2020 ◽  
Vol 10 (1) ◽  
pp. 10-19 ◽  
Author(s):  
A. L. Pylev ◽  
A. A. Zhandarova ◽  
K. S. Petrov ◽  
D. S. Romanov ◽  
V. A. Lisovoy ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Thyroid Cancer ◽  
Primary Tumor ◽  
Molecular Genetic ◽  
Poor Response ◽  
Anaplastic Thyroid Cancer ◽  
Thyroid Tumor ◽  
Surgical Removal ◽  
Genetic Characteristics ◽  
Treatment Methods

Anaplastic thyroid cancer is one of the most prognostically unfavorable tumors. This disadvantage traditionally consisted of a rapid increase in the size of the primary tumor with a tendency to the development of asphyxia and the rapid appearance of distant metastases, as well as a poor response to the recommended treatment methods. The result of many years of efforts by oncologists around the world were several treatment regimens, including an ideal amount of surgical intervention, chemotherapy and radiation therapy, but the effectiveness of this treatment, as well as the patient’s life expectancy after it, could not be called satisfactory. Improving the understanding of the molecular genetic characteristics of tumors, including anaplastic thyroid cancer, provided us with information on two possible features of the genetic apparatus of tumor cells that can have clinical significance: V600E mutations in the BRAF gene and fusion of NTRK genes. The clinical example described in this article is probably the first Russian illustration of the effectiveness of anti-BRAF therapy in a patient with anaplastic thyroid cancer. From our point of view, the benefit of this example is not only to demonstrate the effectiveness of modern targeted therapy, but also the need not to abandon other treatment methods, in this case, radiation therapy to the area of the primary tumor (and by analogy with this, surgical removal of the thyroid tumor glands in case of its resectability).

scholarly journals Inhibition of Survivin with YM155 Induces Durable Tumor Response in Anaplastic Thyroid Cancer

2015 ◽  
Vol 21 (18) ◽  
pp. 4123-4132 ◽  
Author(s):  
Amit Mehta ◽  
Lisa Zhang ◽  
Myriem Boufraqech ◽  
Yi Liu-Chittenden ◽  
Yaqin Zhang ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Response ◽  
Anaplastic Thyroid Cancer

Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview

2021 ◽  
Vol 28 (1) ◽  
pp. 15-26
Author(s):  
Clotilde Sparano ◽  
Yann Godbert ◽  
Marie Attard ◽  
Christine Do Cao ◽  
Slimane Zerdoud ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Response ◽  
Therapeutic Option ◽  
Anaplastic Thyroid Cancer ◽  
External Beam Irradiation ◽  
Off Label ◽  
Limited Efficacy ◽  
Heavily Pretreated ◽  
Poorly Differentiated ◽  
Mixed Tumors

Anaplastic thyroid cancer (ATC) is a rare lethal disease. Lenvatinib is an off-label therapeutic option for ATC in most countries, except in Japan. The aim of this multicenter retrospective survey was to analyze the efficacy and the toxicity profile of off-label lenvatinib treatment in all adults advanced ATC patients, in France. Of the 23 patients analysed (14 males; mean age 64 years), 15 were pure ATC and 8 were mixed tumors (i.e. with a differentiated or poorly differentiated component). Prior treatments included neck external beam irradiation in 74%, at least one line of chemotherapy in 22 cases, two lines of chemotherapy in 11 patients, other TKI in 4 cases. A central RECIST assessment was performed. Since lenvatinib initiation, median PFS was 2.7 months (95% CI; 1.9–3.5) and median OS was 3.1 months (95% CI; 0.6–5.5). OS was significantly longer in case of mixed tumors compared with pure ATC (6.3 vs 2.7 months, P = 0.026). Best tumor response was partial response in two cases and stable disease in seven. Clinical improvement was achieved in seven patients. Lethal adverse events occurred in three patients, consisting in haemoptysis in two cases and pneumothorax in one case. Among long-surviving ATC patients (>6 months), four underwent biopsy of distant metastasis, revealing poorly differentiated histology; three of them had initial mixed ATC histology. Efficacy of lenvatinib appears limited, although pure vs mixed ATC disclose differences in disease aggressiveness and treatment response. Long-surviving ATC patients might benefit from biopsy of persistent disease, searching for histological transition or molecular target.

Sign in / Sign up

Export Citation Format

Share Document